pramipexole
Selected indexed studies
- Pramipexole for the Treatment of Depression: Efficacy and Mechanisms. (Curr Top Behav Neurosci, 2024) [PMID:37982928]
- Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. (Lancet Psychiatry, 2025) [PMID:40602411]
- Classics in Chemical Neuroscience: Pramipexole. (ACS Chem Neurosci, 2020) [PMID:32786316]
_Worker-drafted node — pending editorial review._
Connections
pramipexole is a side effect of
Sources
- Pramipexole for the Treatment of Depression: Efficacy and Mechanisms. (2024) pubmed
- Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. (2025) pubmed
- Classics in Chemical Neuroscience: Pramipexole. (2020) pubmed
- [Pramipexole in bipolar depression: a literature review and clinical recommendations]. (2021) pubmed
- Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. (2019) pubmed
- Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial. (2025) pubmed
- Pramipexole extended release in Parkinson's disease. (2011) pubmed
- Pramipexole extended release: in Parkinson's disease. (2010) pubmed
- Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis. (2022) pubmed
- Pramipexole modulates fronto-subthalamic pathway in sequential working memory. (2023) pubmed